Penumbra Files Second-Quarter 10-Q Ahead of Earnings Release
The medical device company submitted its quarterly report to the SEC, with full Q2 2026 results expected within 24 hours.
Regulatory Filing Precedes Earnings
Penumbra Inc. (PEN) filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on Thursday, the standard regulatory disclosure required of publicly traded companies. The Alameda, California-based medical device manufacturer, which specializes in neurovascular and peripheral vascular therapies, submitted the filing ahead of its scheduled second-quarter 2026 earnings release.
According to MarginX data, Penumbra is expected to report full Q2 2026 results on July 31, 2026, just one day following the 10-Q submission. The company's shares closed at $319.83, valuing the firm at approximately $13 billion.
Recent Insider Transactions
Recent insider activity shows mixed signals among Penumbra executives and directors. MarginX data indicates that Adam Elsesser gifted 77,000 shares, while Harpreet Grewal sold 100 shares. Additionally, Lambert Shiu had 150 shares withheld for tax purposes, a common occurrence related to equity compensation vesting.
The 10-Q filing provides detailed financial information for the quarter ended June 30, 2026, including unaudited financial statements, management's discussion and analysis of financial condition, and disclosures about market risk and controls. Investors and analysts typically review these filings for insights into revenue trends, operating expenses, and management commentary on business conditions.
Looking Ahead
Beyond the imminent earnings release, MarginX data shows several key dates on the horizon for market participants tracking Penumbra. The Federal Reserve's next FOMC meetings with rate decisions are scheduled for September 16 and October 28, 2026, potentially affecting broader market sentiment for growth-oriented healthcare stocks. Penumbra's next quarterly report is expected on November 3, 2026, for the third quarter.
The medical device sector has faced a complex operating environment, balancing procedure volume recovery with supply chain management and evolving reimbursement dynamics. Penumbra's upcoming earnings call should provide additional color on these factors.
This article was generated by MarginX from public news on 2026-07-30. It is not investment advice.